title: Immunophenotypic analyses of CD34(+) cell subsets in bone marrow from HIV-infected patients during highly- active antiretroviral therapy.
abstract: BACKGROUND
  Because increased bone marrow lymphopoiesis might contribute to immunologic reconstitution during highly-active antiretroviral therapy (HAART), we examined the effect of HAART on CD34(+) cell subsets in bone marrow from HIV-infected patients.
  
  
  METHODS
  In 12 HIV-infected patients, bone marrow and peripheral blood were collected before then 4 and 26 weeks after initiating HAART. Bone marrow in 28 HIV-seronegative controls was also examined. Immunophenotypic analyses of CD34(+) cell subsets in bone marrow were performed by flow cytometry.
  
  
  RESULTS
  Our main findings in bone marrow were: (i) HIV-infected patients had increased proportions of CD34(+)cells expressing T- and B-cell markers before initiating HAART; (ii) in contrast, these patients had decreased proportions of CD34(+) cells expressing myeloid-associated markers; (iii) although HAART induced an increase in peripheral T-cell counts, the percentage of CD34(+)cells expressing T-cell markers tended to decrease during such therapy; (iv) HAART induced a decrease in serum IgG accompanied by a slight decrease in the proportion of CD34(+)cells expressing B-cell markers; (v) in contrast, HAART induced a significant increase in peripheral granulocyte counts, accompanied by a slightly increased proportion of CD34(+) cells expressing myeloid-associated molecules.
  
  
  CONCLUSIONS
  Our findings are compatible with an HIV-related block in T-cell differentiation, leading to accumulation of T-cell progenitors in bone marrow, and such a block may be removed by HAART.
authors.affiliation: The National Hospital, University of Oslo, Norway.
authors.forename: F
authors.initials: F
authors.lastname: Müller
authors.forename: G E
authors.initials: GE
authors.lastname: Tjønnfjord
authors.forename: I
authors.initials: I
authors.lastname: Nordøy
authors.forename: D
authors.initials: D
authors.lastname: Kvale
authors.forename: O J
authors.initials: OJ
authors.lastname: Mellbye
authors.forename: P
authors.initials: P
authors.lastname: Aukrust
authors.forename: S S
authors.initials: SS
authors.lastname: Frøland
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis*; D023241:Antiretroviral Therapy, Highly Active; D001854:Bone Marrow Cells / Q000276:immunology*; D016022:Case-Control Studies; D005260:Female; D005434:Flow Cytometry; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016130:Immunophenotyping; D019469:Indinavir / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D018119:Stavudine / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D015215:Zidovudine / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D018952:Antigens, CD34; D017320:HIV Protease Inhibitors; D007074:Immunoglobulin G; D001613:beta 2-Microglobulin; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D018119:Stavudine